In addition to providing up to USD 500,000 in funding, BaseLaunch closely collaborates with the founders connecting them to its partners that include leading pharma companies and venture funds and bringing in relevant consultants, advisors and biopharma professionals. The support ranges from providing access to best-in-class scientific avenues to defining key milestones to de-risk the science or sharpening their overall positioning. BaseLaunch has supported the first companies in 2018, and our portfolio has raised more than USD 270 Million in financing to date.
Two new companies have been added to the BaseLaunch portfolio:
InCephalo, is a preclinical stage spin-off from the University of Zurich, working on new therapies for disorders of the Central Nervous System (CNS). The company has developed a novel technology to optimize antibodies and antibody-fragment biologics for improved efficacy and safety upon local CNS administration. According to a description of the start-up on the website of the University of Zurich, preclinical results point towards a truly local CNS therapy with high concentration in the CNS and lowered risk of systemic side effects. The technology was developed to circumvent the CNS's natural protective mechanism, which has previously only allowed to administer small amounts of active substances to the CNS, and which led to a quick export of these active substances into the blood circulation. InCephalo’s first asset is a treatment of recurrent glioblastoma. A pipeline of additional assets is being built in relevant disease indications such as multiple sclerosis and Parkinson’s disease.
NextImmune, is a spin-off from the Biozentrum, University of Basel, and is focused on the research and development of a novel class of immunosuppressive therapies for autoimmune-inflammatory diseases and organ transplantation.
(Press release / SK)